Background: The use of multisource feedback (MSF) for assessing physician performance is widespread and rapidly growing. Findings from early very small research studies using highly selected participants suggest high levels of satisfaction and support. However, after nearly two decades of experience using MSF to evaluate all physicians in Alberta, we are sceptical of this.
Objectives: To determine physicians' actual opinions of MSF using the entire physician population of Alberta, Canada DESIGN: Online survey.
Setting: Alberta, Canada.
Participants: All physicians with a full licence to practice in Alberta in 2015.
Interventions: All participants were asked to grade how well they thought MSF was at assessing various aspects of physician performance using a 10-point Likert-type scale. There was also a text response field for written comments.
Outcomes: Mean responses to quantitative questions. Qualitative content and thematic analysis of open-ended text responses.We analysed the data using SPSS V.23 and NVivo V.11 and built a multivariate model highlighting the predictors of high and low opinions of MSF.
Results: Survey response rate was high for physicians with 2215 responses (25%). The mean rating for how successful MSF was at assessing a variety of dimensions, varied from a low of 5.03/10 for medical knowledge to a high of 6.38/10 for professionalism and communication. Canadian-trained MDs rated MSF significantly lower on every dimension by approximately 20% compared with non-Canadian-trained MDs.
Conclusions: Alberta physicians have much lower opinions about the ability of MSF to measure any dimension of their performance than what has been suggested in the literature. Canadian-trained MDs have a particularly low opinion of MSF for reasons that remain unclear. The results of this survey offer a serious challenge to the effectiveness of a programme that is designed to promote self-reflection and performance improvement.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371216 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2020-037610 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.
Mult Scler
December 2024
EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, USA.
Background: CLASSIC-MS explored long-term outcomes of patients treated with cladribine tablets.
Objective: Assess long-term efficacy in patients previously enrolled in ORACLE-MS, a Phase III parent trial.
Methods: ORACLE-MS included patients with a first clinical demyelinating event (FCDE or clinically isolated syndrome) who received ⩾1 course of cladribine tablets or placebo.
Establishment of cancer cell radiosensitivity database linked to multi-layer omics data.
Cancer Sci
December 2024
Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
Article Synopsis
- Personalized radiotherapy tailored to individual tumor sensitivities is still under development, and analyzing cancer radiosensitivity with omics data is essential for progress.
- A new database was created from the Cancer Cell Line Encyclopedia (CCLE) to provide radiosensitivity data, using deep learning to sift through literature and extract survival fraction (SF) data from 926 studies on 285 cancer cell lines across 28 types.
- Results revealed significant variations in radiosensitivity between cell lines, with blood cancers showing lower survival fractions than solid tumors, and specific protein levels correlating with radiosensitivity, highlighting the database's potential for future research.
Advances in tuberculosis biomarkers: unravelling risk factors, active disease and treatment success.
Breathe (Sheff)
October 2024
Division of Infection and Global Health, School of Medicine, University of St Andrews, St Andrews, UK.
Tuberculosis (TB) is a major global health threat and demands improved diagnostic and treatment monitoring methods. Conventional diagnostics, such as sputum smear microscopy and culture, are limited by slow results and low sensitivity, particularly in certain patient groups. Recent advances in biomarker research offer promising solutions in three key areas: risk of disease, diagnosis of active disease and monitoring of treatment response.
View Article and Find Full Text PDFOcrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
Neurology
December 2024
From the Department of Neurology (H.-P.H.), UKD, Centre of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), University of Sydney, Australia; Department of Neurology (H.-P.H.), Palacky University Olomouc, Czech Republic; Department of Neurology (R.H.B.B.), Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, NY; Department of Neurology (T.B.), Medical University of Vienna, Comprehensive Center for Clinical Neurosciences and Mental Health, Austria; Mellen Center for MS (R.A.B.), Cleveland Clinic, OH; Neurocentre Magendie INSERM (B.B.), Université de Bordeaux, France; Department of Neurology (W.M.C.), Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands; Department of Medicine and the Ottawa Hospital Research Institute (M.S.F.), University of Ottawa, Ontario, Canada; Department of Neurology (T.H.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H.), University of Oslo, Norway; Department of Neurology (R.K.), Hacettepe University Faculty of Medicine, Ankara, Turkey; Centre d'Esclerosi Mútiple de Catalunya (Cemcat) (C.N.), Vall d'Hebron Hospital Universitari, Barcelona, Spain; Department of Medical and Surgical Sciences and Advanced Technologies (F.P.), GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Italy; Loyola University Chicago (A.P.R.), IL; Department of Neurology (L.V.), AZ Sint-Jan Brugge-Oostende, Belgium; Department of Neurology (T.V.), University of Colorado School of Medicine, Aurora; Medical Image Analysis Center (MIAC AG) (J.W.), Department of Biomedical Engineering, University of Basel; F. Hoffmann-La Roche Ltd (J.W., S.C., K.K., T.K., I.K., C.R., G.-A.T.), Basel, Switzerland; and Department of Neurology (J.K.), VU University Medical Centre, Amsterdam, the Netherlands.
Background And Objectives: Early treatment of multiple sclerosis (MS) reduces disease activity and the risk of long-term disease progression. Effectiveness of ocrelizumab is established in relapsing MS (RMS); however, data in early RMS are lacking. We evaluated the 4-year effectiveness and safety of ocrelizumab as a first-line therapy in treatment-naive patients with recently diagnosed relapsing-remitting MS (RRMS).
View Article and Find Full Text PDFUtilization of Syndromic Vaginitis Diagnostic Testing Reduces 6-Month Follow-Up Outpatient Service Healthcare Costs-A Real-World Data Analysis.
Healthcare (Basel)
November 2024
HealthTrackRx, 1500 I-35 W, Denton TX 76207, USA.
Background/objectives: Vaginitis is a common infection among women of reproductive age. Although various diagnostic methodologies exist, diagnosis without the utilization of available diagnostic tests remains prevalent. This study aimed to assess downstream healthcare utilization and the cost of patients with and without diagnostic testing.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!